Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026

SPRUCE BIOSCIENCES, INC.

Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.
FDA confirmed HS-NRE biomarker may reasonably predict clinical benefit and could support accelerated approval.
BLA submission for TA-ERT anticipated in first half of 2026; fast-track, orphan, and rare pediatric designations granted.
Cash and cash equivalents $38.8M as of Dec 31, 2024; expected cash runway through end of 2025.
42.2M shares outstanding, 21.4M reserved for warrants and equity as of Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.